XML 47 R29.htm IDEA: XBRL DOCUMENT
v3.21.1

Segment Information (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2021
Segment Reporting [Abstract] |
Disaggregation of Revenue [Table Text Block] |
| Three Months Ended March 31,
(in millions) | 2021 |  | 2020
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 34,903 |  |  | $ | 34,899 |
Nuclear and Precision Health Solutions | 201 |  |  | 213 |
Pharmaceutical segment revenue | 35,104 |  |  | 35,112 |
Medical distribution and products (3) | 3,638 |  |  | 3,539 |
Cardinal Health at-Home Solutions | 536 |  |  | 512 |
Medical segment revenue | 4,174 |  |  | 4,051 |
Total segment revenue | 39,278 |  |  | 39,163 |
Corporate (4) | (3) |  |  | (6) |
Total revenue | $ | 39,275 |  |  | $ | 39,157 |
| Nine Months Ended March 31,
(in millions) | 2021 |  | 2020
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 106,859 |  |  | $ | 103,612 |
Nuclear and Precision Health Solutions | 593 |  |  | 642 |
Pharmaceutical segment revenue | 107,452 |  |  | 104,254 |
Medical distribution and products (3) | 10,805 |  |  | 10,483 |
Cardinal Health at-Home Solutions | 1,636 |  |  | 1,508 |
Medical segment revenue | 12,441 |  |  | 11,991 |
Total segment revenue | 119,893 |  |  | 116,245 |
Corporate (4) | (12) |  |  | (12) |
Total revenue | $ | 119,881 |  |  | $ | 116,233 |
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services." (2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block] | The following tables present revenue by geographic area:
| Three Months Ended March 31,
(in millions) | 2021 |  | 2020
United States | $ | 38,089 |  |  | $ | 38,073 |
International | 1,189 |  |  | 1,090 |
Total segment revenue | 39,278 |  |  | 39,163 |
Corporate (1) | (3) |  |  | (6) |
Total revenue | $ | 39,275 |  |  | $ | 39,157 |
| Nine Months Ended March 31,
(in millions) | 2021 |  | 2020
United States | $ | 116,425 |  |  | $ | 113,053 |
International | 3,468 |  |  | 3,192 |
Total segment revenue | 119,893 |  |  | 116,245 |
Corporate (1) | (12) |  |  | (12) |
Total revenue | $ | 119,881 |  |  | $ | 116,233 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following tables present segment profit by reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2021 |  | 2020
Pharmaceutical | $ | 511 |  |  | $ | 534 |
Medical | 174 |  |  | 178 |
Total segment profit | 685 |  |  | 712 |
Corporate | (212) |  |  | (150) |
Total operating earnings | $ | 473 |  |  | $ | 562 |
| Nine Months Ended March 31,
(in millions) | 2021 |  | 2020
Pharmaceutical | $ | 1,326 |  |  | $ | 1,394 |
Medical | 640 |  |  | 543 |
Total segment profit | 1,966 |  |  | 1,937 |
Corporate | (1,656) |  |  | (6,305) |
Total operating earnings/(loss) | $ | 310 |  |  | $ | (4,368) |
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at:
(in millions) | March 31, 2021 |  | June 30, 2020
Pharmaceutical | $ | 23,078 |  |  | $ | 22,398 |
Medical (1) | 15,280 |  |  | 14,691 |
Corporate | 5,516 |  |  | 3,677 |
Total assets | $ | 43,874 |  |  | $ | 40,766 |
(1)Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March 31, 2021.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration